Clinical study of Travoprost(Travatan) in treating patients with refractory glaucoma

Obeject To evaluate the clinical effect and side effect of travoprost in treating patients with refractory glaucoma.Methods The cases were 20 eyes of 20 patients with refractory glaucoma.All eyes had at least one surgery and fail to control IOL.All patients with travoprost one drop at night once daily were studied.The observed signs included IOP(measured at the same time on the one and six month,and 8:00,11:00,14:00,16:00 at one day on six month),visual acuity,visual field and complications.Results The IOP was 27.8 mm Hg before using travoprost(from 24 to 33 mm Hg),One month after treatment,the IOP was 18.6 mm Hg(from 16 to 24 mm Hg).The last IOP was 18.3 mm Hg(from 15 to 25 mm Hg),After 6 months,IOP reductions had no obvious difference when measured at different time on the same day(P0.05).There were no change of visual acuity,optic nerve and visual field before and after using travoprost.All cases appeared conjunctival congestion,but they were 1～2 grade besides of 3 eyes were 3 grade,and all eyes eased with the extension of time,furthermore,2 eyes had pigmentation on preorbit.Eyelashes of 2 eyes becoming rougher and longer.Except above described symptom,no other advere reaction both local and systemic were observed,and no cases interrupted the treatment because of the Side Effects.Conclusion It is demonstrated that travoprost is effective and safe in reducing IOP in refractory glaucoma.It is reliable and easy to use,and in the meanwhile,it had good patients compliance and small side effects.